SALT LAKE CITY, UT -- (Marketwired) -- 08/21/14 -- Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that the Company has been invited to present at the Swedish-American Life Science Summit 2014 to be held in Stockholm, Sweden on August 20-22, 2014.
The Swedish-American Life Science summit is now in its tenth year. This invitation-only event is focusing this year on "The Future of Medicine" and will present an intense and exclusive two-day program featuring high-level panel discussions, insights from keynote speakers and some of the best known life science executives and investors in the world.
Mahendra Rao, MD, Ph.D., Chief Strategy Officer and Chairman of the Scientific Advisory Board, will be participating in a panel discussion, titled "Aging and Regenerative Research, Driving the Future of Medicine," moderated by Anders Hamsten, President of Karolinska Institute. The panel discussion will take place on Thursday, August 21st at 2:00 PM at the EY Headquarters, Stockholm, Sweden.
EVENT AT A GLANCE
Steve Borst - CFO and Vice President, Corporate Development
Mahendra Rao, MD, Ph.D. - Chief Strategy Officer and Chairman of the Scientific Advisory Board
August 21, 2014
Panel Discussion - 2:00 PM
Presentation - 3:00 PM
EY Headquarters, Stockholm, Sweden
About Q Therapeutics, Inc.
Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases and injuries, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), Huntington's disease, spinal cord injury, traumatic brain injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2014. The Company's proprietary product pipeline also encompasses neural cell products derived from induced pluripotent stem cells (iPSC). For more information, visit www.qthera.com.